Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Drug-Resistant TB

Tuberculosis (TB) is a disease caused by bacteria that are spread from person to person through the air. TB usually affects the lungs, but it can also affect other parts of the body, such as the brain, the kidneys, or the spine. In most cases, TB is treatable and curable; however, people with TB can die if they do not get proper treatment.

Sometimes TB bacteria become resistant to the drugs used to treat TB. This means that the drug can no longer kill the bacteria.

Drug-resistant TB can occur when the drugs used to treat TB are misused or mismanaged. Examples include:

  • When people do not complete the full course of treatment;
  • When health care providers prescribe the wrong treatment, the wrong dose, or wrong length of time for taking the drugs;
  • When the supply of drugs is not always available; or
  • When the drugs are of poor quality.

Drug-resistant TB is more common in people who:

  • Do not take their TB drugs regularly
  • Do not take all of their TB drugs
  • Develop TB disease again, after being treated for TB disease in the past
  • Come from areas of the world where drug-resistant TB is common
  • Have spent time with someone known to have drug-resistant TB disease

Drug-resistant TB is spread the same way that drug susceptible TB is spread. TB is spread through the air from one person to another. The TB bacteria are put into the air when a person with TB disease of the lungs or throat coughs, sneezes, speaks, or sings. People nearby may breathe in these bacteria and become infected.

Multidrug-Resistant TB (MDR TB)

Multidrug-resistant TB (MDR TB) is caused by an organism that is resistant to at least isoniazid and rifampin, the two most potent TB drugs. These drugs are used to treat all persons with TB disease.

Extensively Drug-resistant TB (XDR TB)

Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).

Because XDR TB is resistant to the most potent TB drugs, patients are left with treatment options that are much less effective.

XDR TB is of special concern for people with HIV infection or other conditions that can weaken the immune system. These people are more likely to develop TB disease once they are infected, and also have a higher risk of death once they develop TB.

Preventing Drug-Resistant TB

The most important way to prevent the spread of drug-resistant TB is to take all TB drugs exactly as prescribed by the health care provider. No doses should be missed and treatment should not be stopped early. People receiving treatment for TB disease should tell their health care provider if they are having trouble taking the drugs.

Health care providers can help prevent drug-resistant TB by quickly diagnosing cases, following recommended treatment guidelines, monitoring patients’ response to treatment, and making sure therapy is completed.

Another way to prevent getting drug-resistant TB is to avoid exposure to known drug-resistant TB patients in closed or crowded places such as hospitals, prisons, or homeless shelters. People who work in hospitals or health-care settings where TB patients are likely to be seen should consult infection control or occupational health experts.

The Costly Burden of MDR and XDR TB in the U.S.

The first graphic shows the average treatment costs per case in 2010 dollars. The average cost to treat to treat drug-susceptible TB is $17,000; $134,000 to treat MDR TB; and $430,000 to treat XDR TB. If you include productivity losses experienced by patients while undergoing treatment, costs are even higher. The average treatment cost for MDR Tb with productivity loss is $260,000 and $554,000 for XDR TB. The second graphic shows the major human cost of drug-resistant TB. Of those treated for drug-resistant TB 9% died during treatment; 27% stopped working; 73% were hospitalized; and 37% required home isolation. The third graphic shows the percentage of patients that experience severe treatment side effects. Of those treated for drug-resistant TB 19% experienced depression/psychosis; 13% experienced hearing impairment; 13% experienced hepatitis; 11% experiences kidney impairment; 8% experienced loss of mobility; 7% experienced vision impairment; and 1% experienced seizures. The fourth graphic outlines the steps required to prevent and control MDR and XDR TB in the U.S. such as better treatment options, rapid diagnosis, expert treatment of every TB case, and improving global TB diagnosis and treatment. While MDR TB and XDR TB are relatively rare in the U.S., their treatment comes at a terrible price – it is very expensive, takes a long time to complete, disrupts lives, and has potentially life-threatening side effects. A substantial proportion of patients treated for these forms of drug-resistant TB experience serious side effects, including: depression or psychosis, hearing loss, hepatitis, and kidney impairment.

Economic Toll
The average cost of treating a person with TB disease increases with greater resistance. Direct costs (in 2010 U.S. dollars) average from $17,000 to treat drug-susceptible TB to $430,000 to treat the most drug-resistant form of the disease (XDR TB). When including productivity losses (e.g., lost income) experienced by patients while undergoing treatment, costs are even higher.

Contact Us:
  • Centers for Disease Control and Prevention
    Division of Tuberculosis Elimination (DTBE)
    1600 Clifton Rd., NE
    MS E10
    Atlanta, GA 30329
  • 800-CDC-INFO
    TTY: (888) 232-6348
  • Contact CDC–INFO
  • Page last reviewed: June 28, 2012
  • Page last updated: April 1, 2014 The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO